|
|
||||||
|
|
|
|
|
|
|
|
|
|
||||||
ApoLife: HomeApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and next generation antibodies and subunit vaccines through its proprietary Twin Cassette® yeast system.ApoLife employs Bakers yeast (S.cerevisiae) which has been used for manufacturing several FDA approved therapeutic products thus giving ApoLife a competitive regulatory advantage over companies using other yeast systems. ApoLife’s platform has the capability to make fully functional secreted antibodies and has potential to improve antibody potency. The technology has the capability to accelerate the process of identifying and selecting antibodies for target antigens, reducing the cost and development time by up to 50% of the current process. ApoLife uses its technology to develop proprietary anticancer antibodies and immunotoxins with collaborating partners. As a licensing partner, ApoLife has novel proprietary vectors, yeast strains, and production process available for antibody and biogeneric product development. |
||
 |
||